Enanta Pharmaceuticals
ENTA
ENTA
159 hedge funds and large institutions have $1.02B invested in Enanta Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 64 increasing their positions, 48 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
3% more funds holding
Funds holding: 154 → 159 (+5)
2.61% less ownership
Funds ownership: 97.69% → 95.08% (-2.6%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Holders
159
Holding in Top 10
3
Calls
$11.7M
Puts
$1.26M
Top Buyers
| 1 | +$5.37M | |
| 2 | +$5.35M | |
| 3 | +$2.84M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.72M |
| 5 |
Barclays
London,
United Kingdom
|
+$2.05M |
Top Sellers
| 1 | -$16.7M | |
| 2 | -$7.44M | |
| 3 | -$7.01M | |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$5.92M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$3.9M |